What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Portfolio Pulse from Benzinga Insights
Eight analysts have provided ratings for Arcutis Biotherapeutics (NASDAQ:ARQT) in the last quarter, with an average price target of $25.62, implying a significant upside from the current price of $2.49. The current average has decreased by 35.3% from the previous average price target of $39.60.
November 06, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a bullish outlook on Arcutis Biotherapeutics (ARQT) with an average price target of $25.62, indicating a significant potential upside.
The average price target given by the analysts is significantly higher than the current price of the stock, indicating a bullish outlook. However, the decrease in the average price target from the previous quarter could indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100